Guardian Pharmacy tops Q1 revenue estimates, maintains 2026 revenue forecast

Guardian Pharmacy Services

06/05/2026 21:17

Overview

US long-term care pharmacy's Q1 revenue rose 2% yr/yr, beating analyst expectations

Adjusted EPS for Q1 rose to $0.29; no analyst estimates provided

Company raised FY 2026 Adjusted EBITDA guidance and completed upsized secondary share offering

Outlook

Company raises 2026 adjusted EBITDA forecast to $123 mln-$127 mln from $120 mln-$124 mln

Company maintains 2026 revenue outlook at $1.40 bln-$1.42 bln

Company says industry adapting to Inflation Reduction Act; expects to navigate ongoing changes

Result Drivers

RESIDENT GROWTH - Co said 10% increase in residents served and higher prescription volumes supported Q1 results

IRA PRICING IMPACT OFFSET - Co said it offset profitability impact from IRA-related branded drug pricing resets, maintaining margin stability

MANUFACTURER CREDIT - Updated guidance reflects $3 mln in discrete benefits, mainly from a manufacturer inventory credit associated with the IRA

Company press release: ID:nBwb8WjHla

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$336.60 mln
$329.49 mln (5 Analysts)
Q1 Adjusted EPS
$0.29
Q1 EPS
$0.21
Q1 Net Income
$13.54 mln
Q1 Adjusted EBITDA
$29.75 mln
Q1 Gross Profit
$76.31 mln
Q1 Operating Income
$17.68 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the drug retailers peer group is "buy."

Wall Street's median 12-month price target for Guardian Pharmacy Services Inc is $41.00, about 10.1% above its May 5 closing price of $37.24

The stock recently traded at 30 times the next 12-month earnings vs. a P/E of 29 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)